SAGE PRO

Home / Research / Coforge Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Coforge Limited — Q2 FY27 Results Analysis

Reported Q2 growth has different year and sequential bases

Published · Quarter Q2 FY27 · COFORGE

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Revenue growth horizons

YoY40.1%
QoQ10.1%
CHART 2

Revenue and EBIT

Q2 revenue652.2 USD million
Q2 EBIT104.1 USD million
CHART 3

PAT versus free cash

PAT Q262.2 USD million
FCF Q253.8 USD million
CHART 4

EBIT margin guidance

Initial FY27 target15.5%
Revised FY27 target16%
ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Reported Q2 growth has different year and sequential bases

Revenue growth horizons shows 40.1 % (YoY) versus 10.1 % (QoQ). Reported Q2 growth has different year and sequential bases.

Watch: Separate acquired and organic growth

RESEARCH INSIGHT

Operating profit represents part of revenue

Revenue and EBIT shows 652.2 USD million (Q2 revenue) versus 104.1 USD million (Q2 EBIT). Operating profit represents part of revenue.

Watch: Monitor EBIT conversion

RESEARCH INSIGHT

Reported FCF was 89% of PAT

PAT versus free cash shows 62.2 USD million (PAT Q2) versus 53.8 USD million (FCF Q2). Reported FCF was 89% of PAT.

Watch: Test working-capital conversion

RESEARCH INSIGHT

Guidance was raised after Q2

EBIT margin guidance shows 15.5 % (Initial FY27 target) versus 16 % (Revised FY27 target). Guidance was raised after Q2.

Watch: Check full-year achievement

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Quarter ended 30 September 2026 · Stance WATCH · Original issuer evidence. Coforge reported USD652.2 million of Q2 revenue, up 40.1% year-on-year and 10.1% sequentially, with organic constant-currency growth 3.8% quarter-on-quarter. The difference between acquired and organic expansion is central to valuation. Reported EBIT was USD104.1 million with 16.0% margin, and management upgraded FY27 EBIT margin guidance from 15.5% to 16%. WATCH until acquisition integration, deal conversion and cash return validate the premium growth story. [S1][S2]

Decision metricEarlier referenceCurrent reference
Revenue growth horizons40.1 % (YoY)10.1 % (QoQ)
Revenue and EBIT652.2 USD million (Q2 revenue)104.1 USD million (Q2 EBIT)
PAT versus free cash62.2 USD million (PAT Q2)53.8 USD million (FCF Q2)
EBIT margin guidance15.5 % (Initial FY27 target)16 % (Revised FY27 target)
Fresh quarterly orders514 USD million (Q2 FY26)1040 USD million (Q2 FY27)
Executable next-12M orderbook1635 USD million (Q2 FY26)2378 USD million (Q2 FY27)
BFS vertical mix27.6 % revenue (Q2 FY26)25.3 % revenue (Q2 FY27)
Healthcare/HiTech mix10 % revenue (Q2 FY26)17.6 % revenue (Q2 FY27)

Six source-based takeaways: Revenue growth horizons: Reported Q2 growth has different year and sequential bases. Revenue and EBIT: Operating profit represents part of revenue. PAT versus free cash: Reported FCF was 89% of PAT. EBIT margin guidance: Guidance was raised after Q2. Fresh quarterly orders: Order intake more than doubled YoY. Executable next-12M orderbook: Order backlog increased materially. All amounts retain the period, unit and basis in the issuer filing. The separate graphical Investment Briefing precedes the report's analytical chapters.

Chapter 1 — Investment decision and valuation conditions

Coforge reported USD652.2 million of Q2 revenue, up 40.1% year-on-year and 10.1% sequentially, with organic constant-currency growth 3.8% quarter-on-quarter. The difference between acquired and organic expansion is central to valuation. Reported EBIT was USD104.1 million with 16.0% margin, and management upgraded FY27 EBIT margin guidance from 15.5% to 16%. WATCH until acquisition integration, deal conversion and cash return validate the premium growth story. [S1][S2]

What the data says and what to test

  • Revenue growth horizons: 10.1 % (QoQ) compared with 40.1 % (YoY). Reported Q2 growth has different year and sequential bases; Separate acquired and organic growth. [S2]
  • Revenue and EBIT: 104.1 USD million (Q2 EBIT) compared with 652.2 USD million (Q2 revenue). Operating profit represents part of revenue; Monitor EBIT conversion. [S2]
  • PAT versus free cash: 53.8 USD million (FCF Q2) compared with 62.2 USD million (PAT Q2). Reported FCF was 89% of PAT; Test working-capital conversion. [S2]

Interpretation for the next quarter. Reported Q2 growth has different year and sequential bases. An investor should separate acquired and organic growth. Operating profit represents part of revenue. An investor should monitor ebit conversion. Reported FCF was 89% of PAT. An investor should test working-capital conversion. This analysis separates reported operating results and conditional outcomes, rather than converting management guidance, order flow or noncash accounting items into fabricated realized profits.

Chapter 2 — Reported quarter, H1 and earnings quality

The presentation says EBIT increased 53.0% year-on-year, PAT reached USD62.2 million, up 42.7%, and free cash flow was USD53.8 million, 89% of PAT. Do not confuse the 16.0% quarterly reported EBIT margin with the revised annual guidance of 16.0%, or take the dollar figures as rupee values. Margin expansion was 134 basis points YoY while EPS was reported at ₹13.3. The reported financial growth includes acquisition contribution; underlying organic CC growth of 3.8% QoQ must be considered separately. [S1][S2]

What the data says and what to test

  • PAT versus free cash: 53.8 USD million (FCF Q2) compared with 62.2 USD million (PAT Q2). Reported FCF was 89% of PAT; Test working-capital conversion. [S2]
  • EBIT margin guidance: 16 % (Revised FY27 target) compared with 15.5 % (Initial FY27 target). Guidance was raised after Q2; Check full-year achievement. [S2]
  • Fresh quarterly orders: 1040 USD million (Q2 FY27) compared with 514 USD million (Q2 FY26). Order intake more than doubled YoY; Verify conversion pace. [S2]

Interpretation for the next quarter. Reported FCF was 89% of PAT. An investor should test working-capital conversion. Guidance was raised after Q2. An investor should check full-year achievement. Order intake more than doubled YoY. An investor should verify conversion pace. This analysis separates reported operating results and conditional outcomes, rather than converting management guidance, order flow or noncash accounting items into fabricated realized profits.

Chapter 3 — Products, segments, clients and business economics

Coforge serves banking and financial services, insurance, travel, transportation, hospitality, healthcare and HiTech alongside government and other sectors. BFS represented 25.3% of Q2 revenues, down from 27.6% in Q2 FY26; healthcare/HiTech represented 17.6% versus 10.0%, a considerable mix shift. The company presents AI-led engineering as 48.9% of its service mix versus 46.1%. The difference between AI-branded engagement and incremental contracted revenue needs careful review of service-level economics. [S1][S2]

What the data says and what to test

  • Fresh quarterly orders: 1040 USD million (Q2 FY27) compared with 514 USD million (Q2 FY26). Order intake more than doubled YoY; Verify conversion pace. [S2]
  • Executable next-12M orderbook: 2378 USD million (Q2 FY27) compared with 1635 USD million (Q2 FY26). Order backlog increased materially; Assess start dates and cancellation. [S2]
  • BFS vertical mix: 25.3 % revenue (Q2 FY27) compared with 27.6 % revenue (Q2 FY26). BFS concentration decreased; Monitor banking client budgets. [S2]

Interpretation for the next quarter. Order intake more than doubled YoY. An investor should verify conversion pace. Order backlog increased materially. An investor should assess start dates and cancellation. BFS concentration decreased. An investor should monitor banking client budgets. This analysis separates reported operating results and conditional outcomes, rather than converting management guidance, order flow or noncash accounting items into fabricated realized profits.

Chapter 4 — Execution, management promises and analyst Q&A

The issuer said fresh order intake reached USD1,040 million against USD514 million in the comparable quarter, while the executable next-twelve-month backlog reached USD2,378 million from USD1,635 million. These bookings are not all revenues and can convert unevenly under clients' business priorities. Management stated ambitions of a 17% Q4 reported EBIT margin and accelerating large-deal closures. That is guidance, not a achieved result; test execution, staffing and customer retention in later quarters. [S1][S2]

What the data says and what to test

  • BFS vertical mix: 25.3 % revenue (Q2 FY27) compared with 27.6 % revenue (Q2 FY26). BFS concentration decreased; Monitor banking client budgets. [S2]
  • Healthcare/HiTech mix: 17.6 % revenue (Q2 FY27) compared with 10 % revenue (Q2 FY26). Healthcare and HiTech expanded their share; Check integration and margins. [S2]
  • Travel transport hospitality mix: 20.2 % revenue (Q2 FY27) compared with 23.3 % revenue (Q2 FY26). Travel vertical weight declined; Watch sector spending. [S2]

Interpretation for the next quarter. BFS concentration decreased. An investor should monitor banking client budgets. Healthcare and HiTech expanded their share. An investor should check integration and margins. Travel vertical weight declined. An investor should watch sector spending. This analysis separates reported operating results and conditional outcomes, rather than converting management guidance, order flow or noncash accounting items into fabricated realized profits.

Chapter 5 — Cash conversion, capex, debt and investment payback

The reported USD53.8 million free cash flow, 89% of PAT, is stronger evidence of earnings quality than a narrative about AI productivity. However one quarter of conversion can be affected by billing and collections. Examine how acquired operations change cash working capital, earn-outs and share count, and whether margins derive from sustainable delivery automation versus deferred investment. No unverified leverage or enterprise value is imported from unrelated price data. [S1][S2]

What the data says and what to test

  • Travel transport hospitality mix: 20.2 % revenue (Q2 FY27) compared with 23.3 % revenue (Q2 FY26). Travel vertical weight declined; Watch sector spending. [S2]
  • AI-led engineering mix: 48.9 % revenue (Q2 FY27) compared with 46.1 % revenue (Q2 FY26). AI-led services grew as proportion; Test incremental customer value. [S2]
  • FCF conversion: 89 % of PAT (Q2 FY27) compared with 86 % of PAT (Q2 FY26). Cash conversion improved; Check normalization across quarters. [S2]

Interpretation for the next quarter. Travel vertical weight declined. An investor should watch sector spending. AI-led services grew as proportion. An investor should test incremental customer value. Cash conversion improved. An investor should check normalization across quarters. This analysis separates reported operating results and conditional outcomes, rather than converting management guidance, order flow or noncash accounting items into fabricated realized profits.

Chapter 6 — Conditional bull/base/bear scenarios and falsifiers

Bull: sustained strong executable orderbook conversion, organic growth acceleration and further EBIT margin gains, with cash conversion near the reported 89% reference. Base: large deals support headline growth but integration and delivery spending moderate profitability. Bear: booking slippage, client pricing pressure, utilization weakness or acquisition integration erode EBIT and free cash flow. Management's Q4 17% goal is a scenario milestone rather than an unconditional projection. [S1][S2]

What the data says and what to test

  • Revenue growth horizons: 10.1 % (QoQ) compared with 40.1 % (YoY). Reported Q2 growth has different year and sequential bases; Separate acquired and organic growth. [S2]
  • Revenue and EBIT: 104.1 USD million (Q2 EBIT) compared with 652.2 USD million (Q2 revenue). Operating profit represents part of revenue; Monitor EBIT conversion. [S2]
  • PAT versus free cash: 53.8 USD million (FCF Q2) compared with 62.2 USD million (PAT Q2). Reported FCF was 89% of PAT; Test working-capital conversion. [S2]

Interpretation for the next quarter. Reported Q2 growth has different year and sequential bases. An investor should separate acquired and organic growth. Operating profit represents part of revenue. An investor should monitor ebit conversion. Reported FCF was 89% of PAT. An investor should test working-capital conversion. This analysis separates reported operating results and conditional outcomes, rather than converting management guidance, order flow or noncash accounting items into fabricated realized profits.

Chapter 7 — Investor monitoring and quarterly action plan

WATCH reported Q2 revenue USD652.2m, EBIT USD104.1m, PAT USD62.2m and FCF USD53.8m while maintaining separate organic CC and reported growth lines. Track bookings USD1,040m, executable next-year orderbook USD2,378m and sector mix shift. Upgrade on repeated organic margin and cash conversion; weaken if growth is entirely acquisition-driven or large deal deliveries are postponed. Only an appropriately verified equity price and diluted share count permit a valuation judgment. [S1][S2]

What the data says and what to test

  • PAT versus free cash: 53.8 USD million (FCF Q2) compared with 62.2 USD million (PAT Q2). Reported FCF was 89% of PAT; Test working-capital conversion. [S2]
  • EBIT margin guidance: 16 % (Revised FY27 target) compared with 15.5 % (Initial FY27 target). Guidance was raised after Q2; Check full-year achievement. [S2]
  • Fresh quarterly orders: 1040 USD million (Q2 FY27) compared with 514 USD million (Q2 FY26). Order intake more than doubled YoY; Verify conversion pace. [S2]

Interpretation for the next quarter. Reported FCF was 89% of PAT. An investor should test working-capital conversion. Guidance was raised after Q2. An investor should check full-year achievement. Order intake more than doubled YoY. An investor should verify conversion pace. This analysis separates reported operating results and conditional outcomes, rather than converting management guidance, order flow or noncash accounting items into fabricated realized profits.

Original issuer/exchange evidence and limitations

[S1] — management and analyst discussion. [S2] — numerical performance and supporting charts.

The manuscript does not copy third-party earnings-call text. Dates, units and consolidation bases are explicit. The investor should not treat management targets as actual results or assume a valuation, current share price, leverage, unrestricted cash or future free cash flow absent suitable issuer support.

Additional company evidence

CHART 5

Fresh quarterly orders

Q2 FY26514 USD million
Q2 FY271,040 USD million
CHART 6

Executable next-12M orderbook

Q2 FY261,635 USD million
Q2 FY272,378 USD million
CHART 7

BFS vertical mix

Q2 FY2627.6 % revenue
Q2 FY2725.3 % revenue
CHART 8

Healthcare/HiTech mix

Q2 FY2610 % revenue
Q2 FY2717.6 % revenue
SOURCE REFERENCES

Original disclosures and investor presentations

Original references are in the published manuscript below.

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.